Musculoskeletal Manifestations among Egyptian HCV Patients Receiving Direct Antivirals (DAAS) Therapy
Fortune Journal of Rheumatology · 2022
DOI: 10.26502/fjr.26880032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fortune Journal of Rheumatology, 2022. Verfasst von Marwa A Besar und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Hepatitis C is a worldwide problem; the treatment of chronic HCV has been revolutionized with the introduction of the oral Direct-Acting Antiviral (DAA) drugs. The efficacy in eradication of extrahepatic and hepatic manifestation leads to its widely spread of these medications, but there is musculoskeletal side effect reported with its use.
Objectives
Assess musculoskeletal manifestation in HCV patients receiving Direct Antivirals Therapy (DAATs) attending Rheumatology & Immunology Unit in internal medicine department in Mansoura university Hospital.
Result
Majority of studied patients (n=200) were 64% females and 36% were male. The most frequent involved joint was the knee 55% (110), while the least affected joint was the wrist 6% (12) and the shoulder joint 8%. It was observed that bone pain (71.1%) especially at shoulder joint (64.3%) and back (60.7%) were associated with Sofosbuvir+ Daclatasvir but were statistically insignificant. Arthralgia was presenting manifestation in 63% with patients received Sofosbuvir +Daclatasvir and dominated in the wrist joint (66.7%), knee joint (65.5%), shoulder joint (62.5%) but it was statistically insignificant. Back pain was evident in patients treated by DAAs for 12 weeks (27.7%) than those received it for 24 weeks (11.8%) and it was statistically significant p* = 0.050.
Conclusion
Musculoskeletal disorders reported mainly with sofosbuvir and daclatasvir especially for 12-week duration and the most affected age group (more than 55year).
Zitieren
APA
Besar, M. A., Salam, A. I. A. E., Enin, A. F., & Anter, D. A. (2022). Musculoskeletal Manifestations among Egyptian HCV Patients Receiving Direct Antivirals (DAAS) Therapy. Fortune Journal of Rheumatology. https://doi.org/10.26502/fjr.26880032
Vancouver
Besar MA, Salam AIAE, Enin AF, Anter DA. Musculoskeletal Manifestations among Egyptian HCV Patients Receiving Direct Antivirals (DAAS) Therapy. Fortune Journal of Rheumatology. 2022. doi:10.26502/fjr.26880032
BibTeX
@article{Besar2022,
author = {Besar, Marwa A and Salam, Adel I Abd El and Enin, Asmaa F and Anter, Doaa A},
title = {Musculoskeletal Manifestations among Egyptian HCV Patients Receiving Direct Antivirals (DAAS) Therapy},
journal = {Fortune Journal of Rheumatology},
year = {2022},
doi = {10.26502/fjr.26880032}
}
EUVIMED